InspireMD (NSPR)
Market Price (3/17/2026): $1.65 | Market Cap: $121.2 MilSector: Health Care | Industry: Life Sciences Tools & Services
InspireMD (NSPR)
Market Price (3/17/2026): $1.65Market Cap: $121.2 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -50% | Weak multi-year price returns2Y Excs Rtn is -67%, 3Y Excs Rtn is -35% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -47 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -603% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies. | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 152% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -418%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -438% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -42% | ||
| Key risksNSPR key risks include [1] substantial going concern risk due to recurring losses and negative cash flows, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -50% |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Geriatric Care, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -67%, 3Y Excs Rtn is -35% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -47 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -603% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 152% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -418%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -438% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -42% |
| Key risksNSPR key risks include [1] substantial going concern risk due to recurring losses and negative cash flows, Show more. |
Qualitative Assessment
AI Analysis | Feedback
InspireMD (NSPR) stock has lost about 15% since 11/30/2025 because of the following key factors:
1. Widened Net Loss in Q3 2025 Due to U.S. Commercial Launch Expenses. InspireMD reported its Third Quarter 2025 financial results on November 4, 2025, revealing a net loss that widened to $12.7 million, or $0.17 per share. This increased loss was primarily attributed to higher commercial and infrastructure spending associated with the U.S. launch of its CGuard Prime carotid stent system, despite a 39% year-over-year increase in total revenue to $2.5 million. The stock declined by 7.2% following this earnings announcement.
2. Market Anticipation of Continued Financial Burn from U.S. Expansion. Following the Q3 2025 results, which highlighted significant investment in the U.S. commercial rollout, investors likely anticipated ongoing elevated operating expenses and sustained net losses for subsequent periods. The consensus EPS forecast for Q4 2025, expected to be reported in early March 2026, projected a continued loss of -$0.19 to -$0.22 per share, indicating that the increased spending impacting profitability was expected to persist as the U.S. market penetration for CGuard Prime continued.
Show more
1. Widened Net Loss in Q3 2025 Due to U.S. Commercial Launch Expenses. InspireMD reported its Third Quarter 2025 financial results on November 4, 2025, revealing a net loss that widened to $12.7 million, or $0.17 per share. This increased loss was primarily attributed to higher commercial and infrastructure spending associated with the U.S. launch of its CGuard Prime carotid stent system, despite a 39% year-over-year increase in total revenue to $2.5 million. The stock declined by 7.2% following this earnings announcement.
2. Market Anticipation of Continued Financial Burn from U.S. Expansion. Following the Q3 2025 results, which highlighted significant investment in the U.S. commercial rollout, investors likely anticipated ongoing elevated operating expenses and sustained net losses for subsequent periods. The consensus EPS forecast for Q4 2025, expected to be reported in early March 2026, projected a continued loss of -$0.19 to -$0.22 per share, indicating that the increased spending impacting profitability was expected to persist as the U.S. market penetration for CGuard Prime continued.
Show more
Stock Movement Drivers
Fundamental Drivers
The -17.4% change in NSPR stock from 11/30/2025 to 3/16/2026 was primarily driven by a -17.4% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.98 | 1.64 | -17.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 8 | 8 | 0.0% |
| P/S Multiple | 18.7 | 15.4 | -17.4% |
| Shares Outstanding (Mil) | 73 | 73 | 0.0% |
| Cumulative Contribution | -17.4% |
Market Drivers
11/30/2025 to 3/16/2026| Return | Correlation | |
|---|---|---|
| NSPR | -17.4% | |
| Market (SPY) | -2.1% | 22.7% |
| Sector (XLV) | -4.2% | 11.8% |
Fundamental Drivers
The -33.0% change in NSPR stock from 8/31/2025 to 3/16/2026 was primarily driven by a -30.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 8312025 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.44 | 1.64 | -33.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 8 | 10.1% |
| P/S Multiple | 17.6 | 15.4 | -12.3% |
| Shares Outstanding (Mil) | 51 | 73 | -30.6% |
| Cumulative Contribution | -33.0% |
Market Drivers
8/31/2025 to 3/16/2026| Return | Correlation | |
|---|---|---|
| NSPR | -33.0% | |
| Market (SPY) | 4.0% | 28.1% |
| Sector (XLV) | 10.4% | 13.4% |
Fundamental Drivers
The -49.2% change in NSPR stock from 2/28/2025 to 3/16/2026 was primarily driven by a -34.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.22 | 1.64 | -49.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 7 | 8 | 14.0% |
| P/S Multiple | 22.8 | 15.4 | -32.4% |
| Shares Outstanding (Mil) | 48 | 73 | -34.2% |
| Cumulative Contribution | -49.2% |
Market Drivers
2/28/2025 to 3/16/2026| Return | Correlation | |
|---|---|---|
| NSPR | -49.2% | |
| Market (SPY) | 13.6% | 7.2% |
| Sector (XLV) | 2.7% | 2.2% |
Fundamental Drivers
The 42.2% change in NSPR stock from 2/28/2023 to 3/16/2026 was primarily driven by a 846.4% change in the company's P/S Multiple.| (LTM values as of) | 2282023 | 3162026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.15 | 1.64 | 42.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 6 | 8 | 40.8% |
| P/S Multiple | 1.6 | 15.4 | 846.4% |
| Shares Outstanding (Mil) | 8 | 73 | -89.3% |
| Cumulative Contribution | 42.2% |
Market Drivers
2/28/2023 to 3/16/2026| Return | Correlation | |
|---|---|---|
| NSPR | 42.2% | |
| Market (SPY) | 75.1% | 7.4% |
| Sector (XLV) | 24.3% | 6.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NSPR Return | -41% | -72% | 227% | -6% | -32% | -7% | -68% |
| Peers Return | 4% | -15% | -8% | -24% | 39% | -45% | -53% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -3% | 77% |
Monthly Win Rates [3] | |||||||
| NSPR Win Rate | 25% | 25% | 58% | 33% | 25% | 33% | |
| Peers Win Rate | 56% | 53% | 47% | 42% | 42% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| NSPR Max Drawdown | -43% | -73% | 0% | -34% | -38% | -11% | |
| Peers Max Drawdown | -20% | -41% | -42% | -35% | -16% | -48% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -3% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, ATEC, CERS, AIDX, POAS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/16/2026 (YTD)
How Low Can It Go
| Event | NSPR | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -95.9% | -25.4% |
| % Gain to Breakeven | 2325.9% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -79.2% | -33.9% |
| % Gain to Breakeven | 379.8% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -100.0% | -19.8% |
| % Gain to Breakeven | 685160.4% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to A, ATEC, CERS, AIDX, POAS
In The Past
InspireMD's stock fell -95.9% during the 2022 Inflation Shock from a high on 2/11/2021. A -95.9% loss requires a 2325.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About InspireMD (NSPR)
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
AI Analysis | Feedback
Here are 1-3 brief analogies for InspireMD (NSPR):
- Medtronic for embolic prevention stents.
- Abbott Laboratories for specialized carotid and coronary stents.
AI Analysis | Feedback
- CGuard carotid embolic prevention system: A medical device for preventing embolic events in carotid artery applications.
- MGuard Prime embolic protection systems: Systems designed for embolic protection in patients with acute coronary syndromes and during bypass surgery.
- PVGuard: A MicroNet mesh sleeve and self-expandable stent under development for peripheral vascular applications.
AI Analysis | Feedback
InspireMD (NSPR) primarily sells its products to other companies. Based on the provided company description, its major customers are local distributors operating in Europe, Latin America, the Middle East, and Asia Pacific.
The company description does not provide the specific names of these distributor companies.
AI Analysis | Feedback
nullAI Analysis | Feedback
Marvin Slosman, Chief Executive Officer
Mr. Slosman has over 30 years of experience in the medical device industry, with focused leadership in commercialization and international market development in both public and privately held companies. Prior to joining InspireMD in January 2020, he served as a Business Consultant for Integra LifeSciences, overseeing commercial strategy and market development. He previously served as President of ITAMAR Medical, CEO of Ovalum Vascular, Ltd., a privately held medical device company, and CEO of Phormax Medical, Inc. Mr. Slosman has also held senior commercial leadership positions at Johnson & Johnson, GE Healthcare, and Baxter. His experience includes involvement in IPOs, multiple funding rounds, and M&A transactions.
Michael Lawless, Chief Financial Officer
Mr. Lawless has over two decades of financial leadership experience in the life sciences sector, with a strong track record of driving growth and operational excellence in public companies. Prior to joining InspireMD as Chief Financial Officer (effective on or prior to June 30, 2025), he served as CFO of Lifeward (formerly ReWalk Robotics), a publicly traded medical technology company. Previously, he was the CFO of the $200 million Life Sciences division at Brooks Automation, where he led financial operations and implemented strategies for operational improvements. He possesses deep expertise in capital markets, M&A, investor relations, and financial operations.
Shane Gleason, Chief Commercial Officer
Mr. Gleason brings over 20 years of experience in the medical device industry, having led clinical and commercial operations in both public and privately held companies. Before his promotion to Chief Commercial Officer, he served as InspireMD's General Manager of North America and Vice President of Global Marketing. Prior to joining InspireMD, he was the Vice President of Sales, Vascular Interventions at Surmodics, a medical device company.
Amir Kohen, EVP Finance & Regional Manager
Mr. Kohen has over 20 years of experience in financial and accounting management, including working with global listed companies in the US and Israel. Before joining InspireMD, he spent six years in various management roles at PwC. He holds an MBA in Financial Management.
Sonali Dewan, Vice President of Regulatory & Clinical Affairs and Quality Assurance
Ms. Dewan has over 20 years of global experience in the medical device industry, with leadership roles spanning Regulatory Affairs, Clinical Affairs, and Quality Assurance in both public and privately held companies. Prior to InspireMD, she served as Director of Regulatory Affairs at BlueRock Therapeutics, where she managed global regulatory strategy for drug-device combination products. She also held senior regulatory leadership positions at Medtronic, Johnson & Johnson, Boston Scientific, and St. Jude Medical.
AI Analysis | Feedback
<h3>Key Risks to InspireMD (NSPR)</h3> <ol> <li> <b>Financial Uncertainty and Need for Additional Capital:</b> InspireMD faces significant uncertainty regarding its ability to continue as a going concern due to a history of recurring losses and negative cash flows from operating activities. This financial instability could hinder its capacity to secure necessary additional capital under reasonable terms, impacting future operations and growth prospects.</li> <li> <b>Regulatory Approvals, Clinical Development, and Market Acceptance:</b> The company's success heavily depends on its ability to secure and maintain regulatory approvals for its existing and developing products, such as the CGuard Prime carotid embolic prevention system and PVGuard. Uncertainties surrounding clinical trial results, potential product delays, and the crucial need for market acceptance by healthcare professionals pose significant challenges to commercialization and revenue generation.</li> <li> <b>Intense Competition and Reimbursement Challenges:</b> InspireMD operates in a highly competitive medical device industry with much larger, multi-national companies. Furthermore, its ability to generate revenue is dependent on adequate reimbursement by governmental and other third-party payers for its products, which can be challenging to secure and maintain.</li> </ol>AI Analysis | Feedback
null
AI Analysis | Feedback
InspireMD (NASDAQ: NSPR) operates in several medical device markets, addressing vascular and coronary diseases. The addressable markets for its main products are as follows: * **CGuard Carotid Embolic Prevention System:** InspireMD estimates the addressable market for its CGuard Carotid Stent System and SwitchGuard NPS to be approximately **$1.3 billion globally**, with a potential to grow to $9.3 billion if expanded treatment options lead to increased patient screening. The broader global carotid artery disease market was valued at approximately $12.59 billion in 2025, projected to reach $16.68 billion by 2032. The global carotid artery stenosis therapeutics market was estimated at $5.2 billion in 2023 and is projected to reach $9.5 billion by 2030. In the U.S. alone, the carotid intervention market (CAS/TCAR) is estimated at $691 million in 2025. * **MGuard Prime Embolic Protection Systems:** This product targets patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. The global acute coronary syndrome market was valued at approximately **$9.86 billion in 2024**, projected to reach $13.3 billion by 2029. Other estimates place the global acute coronary syndrome therapeutics market at $9.9 billion in 2025, growing to $17 billion by 2034. For saphenous vein graft applications, the global saphenous vein grafts market size was valued at $1.97 billion in 2024 and is projected to reach $3.00 billion by 2032. The overall global embolic protection devices market, which MGuard Prime falls under, was valued at approximately $648.51 million in 2024 and is expected to increase to $1.16 billion by 2032. Another source estimates the embolic protection systems market size at $711.16 million in 2025, projected to reach $1,060.50 million by 2030. * **PVGuard (in development for peripheral vascular applications):** The global peripheral artery disease (PAD) market was valued at approximately **$5.11 billion in 2024** and is projected to grow at a CAGR of 7.5% from 2025 to 2034. The broader global peripheral vascular devices market, which includes PVGuard, was estimated at $10.44 billion in 2024 and is projected to reach $16.90 billion by 2033. This market is also estimated at $9.85 billion in 2024, expected to increase to $15.54 billion by 2032.AI Analysis | Feedback
InspireMD (NSPR) is poised for future revenue growth over the next 2-3 years, driven by several key factors:
- U.S. Commercial Launch and Expansion of CGuard Prime: A significant driver of revenue growth is the commercial launch of the CGuard Prime carotid stent system in the U.S., which began in July 2025 following FDA premarket approval. The company has been strategically building a commercial and operational team to support this major market entry, aiming to establish CGuard Prime as a new standard for carotid intervention.
- Continued Growth in Existing International Markets: InspireMD expects to see ongoing revenue growth from its established markets in Europe, Latin America, the Middle East, and Asia Pacific. The company's CE Mark recertification in 2022 significantly contributed to growth in these OUS (Outside U.S.) markets. InspireMD's CGuard sales in existing markets have already demonstrated consistent increases, with record CGuard revenue reported in Q4 2023.
- Expansion into New International Markets: The company is actively pursuing a strategy of expanding its global distribution footprint by entering new international markets, particularly in the Asia Pacific region. This strategic geographic expansion contributes to increasing market access for its CGuard products.
- Development and Commercialization of New Products: InspireMD has a pipeline of new products beyond CGuard designed to broaden its portfolio, including those for neurovascular and peripheral indications like PVGuard (as mentioned in the background). The company is also progressing with pivotal studies for devices like the SwitchGuard TCAR, with its clearance and launch anticipated by 2027, signaling future product-driven revenue streams.
- Increasing Adoption and Market Share of CGuard/CGuard Prime: InspireMD aims to establish its MicroNet-based CGuard stent platform as the new standard of care for carotid artery disease. The growing body of clinical data and real-world evidence supporting the safety and efficacy of CGuard is expected to drive its adoption by physicians and increase market share globally.
AI Analysis | Feedback
Share Issuance
- In July 2025, InspireMD raised approximately $58 million in combined gross proceeds from an equity private placement of $40.1 million and the exercise of warrants totaling $17.9 million, following FDA premarket approval for its CGuard Prime carotid stent system.
- During the first quarter of 2021, the company completed an upsized underwritten public offering and other capital raising transactions, generating $35.1 million in net proceeds.
- InspireMD regularly issues restricted stock and stock options as inducement grants to new employees and executives, including 40,513 restricted shares in October 2025, 138,442 restricted shares in February 2025, and 677,000 shares and options to its new CFO in June 2025.
Inbound Investments
- A $40.1 million equity private placement in July 2025 was led by existing investors OrbiMed and Marshall Wace, with contributions from new and current investors, and InspireMD board members.
Capital Expenditures
- Operating expenses in Q3 2025 increased by $5.0 million, primarily driven by higher headcount-related expenses and the establishment of a U.S. headquarters.
- In Q2 2025, operating expenses rose by 55% to $13.3 million, largely due to increased headcount and the setup of the U.S. headquarters.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| How Low Can InspireMD Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to NSPR.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 2.15 |
| Mkt Cap | 1.1 |
| Rev LTM | 485 |
| Op Inc LTM | -28 |
| FCF LTM | -2 |
| FCF 3Y Avg | -18 |
| CFO LTM | 25 |
| CFO 3Y Avg | -16 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 14.2% |
| Rev Chg 3Y Avg | 10.6% |
| Rev Chg Q | 17.1% |
| QoQ Delta Rev Chg LTM | 4.2% |
| Op Mgn LTM | -5.9% |
| Op Mgn 3Y Avg | -14.6% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 4.1% |
| CFO/Rev 3Y Avg | -6.1% |
| FCF/Rev LTM | -0.0% |
| FCF/Rev 3Y Avg | -13.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.1 |
| P/S | 3.5 |
| P/EBIT | -11.1 |
| P/E | -8.0 |
| P/CFO | 32.5 |
| Total Yield | -6.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -4.6% |
| D/E | 0.2 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -8.8% |
| 3M Rtn | -28.2% |
| 6M Rtn | -23.8% |
| 12M Rtn | -24.3% |
| 3Y Rtn | -28.1% |
| 1M Excs Rtn | -11.8% |
| 3M Excs Rtn | -26.2% |
| 6M Excs Rtn | -26.1% |
| 12M Excs Rtn | -44.8% |
| 3Y Excs Rtn | -98.5% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Develops, manufactures and markets products for the treatment of carotid artery disease and other | 6 | ||||
| CGuard™ embolic protection system (EPS) | 5 | 4 | 3 | 3 | |
| MGuard Prime™ embolic protection system (EPS) | 0 | 0 | -0 | 0 | |
| Total | 6 | 5 | 4 | 2 | 4 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Develops, manufactures and markets products for the treatment of carotid artery disease and other | -20 | ||||
| Total | -20 |
Price Behavior
Price Behavior
| Market Price | $1.64 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 04/11/2011 | |
| Distance from 52W High | -41.6% | |
| 50 Days | 200 Days | |
| DMA Price | $1.70 | $2.14 |
| DMA Trend | down | down |
| Distance from DMA | -3.9% | -23.5% |
| 3M | 1YR | |
| Volatility | 49.3% | 56.6% |
| Downside Capture | 168.21 | 111.15 |
| Upside Capture | 73.02 | 34.05 |
| Correlation (SPY) | 22.9% | 6.0% |
NSPR Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.56 | 0.95 | 1.22 | 1.50 | 0.20 | 0.37 |
| Up Beta | 2.34 | 2.87 | 3.41 | 1.60 | -0.13 | 0.01 |
| Down Beta | -0.92 | -0.39 | -0.70 | 1.16 | -0.02 | 0.16 |
| Up Capture | 294% | 76% | 112% | 99% | 19% | 46% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 12 | 22 | 29 | 57 | 107 | 331 |
| Down Capture | 121% | 122% | 174% | 187% | 107% | 91% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 8 | 15 | 26 | 57 | 119 | 359 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NSPR | |
|---|---|---|---|---|
| NSPR | -42.9% | 56.5% | -0.79 | - |
| Sector ETF (XLV) | 6.4% | 17.5% | 0.20 | 2.6% |
| Equity (SPY) | 22.5% | 18.9% | 0.94 | 6.0% |
| Gold (GLD) | 68.7% | 26.2% | 1.98 | 6.4% |
| Commodities (DBC) | 19.7% | 17.3% | 0.91 | -8.7% |
| Real Estate (VNQ) | 9.3% | 16.2% | 0.37 | -1.1% |
| Bitcoin (BTCUSD) | -9.2% | 44.2% | -0.09 | -1.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NSPR | |
|---|---|---|---|---|
| NSPR | -32.2% | 75.4% | -0.20 | - |
| Sector ETF (XLV) | 7.5% | 14.5% | 0.33 | 6.1% |
| Equity (SPY) | 13.1% | 17.0% | 0.60 | 11.1% |
| Gold (GLD) | 23.6% | 17.2% | 1.12 | -0.5% |
| Commodities (DBC) | 11.2% | 19.0% | 0.47 | 1.1% |
| Real Estate (VNQ) | 4.9% | 18.8% | 0.16 | 7.9% |
| Bitcoin (BTCUSD) | 6.1% | 56.7% | 0.33 | 6.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NSPR | |
|---|---|---|---|---|
| NSPR | -79.2% | 117.6% | -0.65 | - |
| Sector ETF (XLV) | 10.1% | 16.5% | 0.50 | 5.6% |
| Equity (SPY) | 14.7% | 17.9% | 0.70 | 8.0% |
| Gold (GLD) | 14.4% | 15.6% | 0.76 | 2.0% |
| Commodities (DBC) | 8.4% | 17.6% | 0.39 | 5.7% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 4.1% |
| Bitcoin (BTCUSD) | 67.9% | 66.8% | 1.07 | 2.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/4/2025 | -0.7% | -23.3% | -11.5% |
| 8/5/2025 | -8.2% | -3.4% | -9.0% |
| 3/12/2025 | 0.7% | 0.4% | -6.8% |
| 8/6/2024 | 0.7% | -4.1% | -10.5% |
| 3/6/2024 | -3.8% | -6.5% | -12.9% |
| 11/6/2023 | -3.0% | -8.9% | -23.1% |
| 8/8/2023 | 0.0% | 1.3% | 12.9% |
| 3/30/2023 | -7.8% | -0.9% | -9.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 4 | 4 | 5 |
| # Negative | 13 | 13 | 12 |
| Median Positive | 0.3% | 0.8% | 12.0% |
| Median Negative | -3.1% | -6.7% | -12.2% |
| Max Positive | 0.7% | 3.7% | 24.3% |
| Max Negative | -19.9% | -39.6% | -28.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/12/2025 | 10-K |
| 09/30/2024 | 11/12/2024 | 10-Q |
| 06/30/2024 | 08/05/2024 | 10-Q |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 03/05/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/30/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 08/08/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 03/07/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Stuka, Paul | Direct | Buy | 12112025 | 1.81 | 5,073 | 9,182 | 708,847 | Form | |
| 2 | Stuka, Paul | Direct | Buy | 12082025 | 1.86 | 5,073 | 9,436 | 723,387 | Form | |
| 3 | Stuka, Paul | Direct | Buy | 12052025 | 1.85 | 10,130 | 18,740 | 710,113 | Form | |
| 4 | Stuka, Paul | Direct | Buy | 11132025 | 1.62 | 13,431 | 21,758 | 605,418 | Form | |
| 5 | Roubin, Gary S | Direct | Buy | 8012025 | 2.42 | 41,322 | 99,999 | 1,472,388 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.